Noticias de Eulerpool Shin Nippon Biomedical Laboratories

Shin Nippon Biomedical Laboratories Noticias de Acciones

Shin Nippon Biomedical Laboratories es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Shin Nippon Biomedical Laboratories.

• 31 de octubre ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
• 8 de octubre ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
• 13 de junio ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
• 17 de julio ·

  SeekingAlpha
  Leaven Partners Second Quarter 2023 Letter To Partners
• 15 de junio ·

  Yahoo
  Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
• 18 de mayo ·

  Yahoo
  Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
• 28 de julio ·

  CNBC
  Stocks making the biggest moves midday: Bausch Health, Meta, Comcast, Qualcomm and more
• 28 de julio ·

  CNBC
  Comcast earnings beat Wall Street's estimates, reports flat broadband subscribers
• 28 de julio ·

  CNBC
  Stocks making the biggest moves in the premarket: Stanley Black & Decker, Southwest Airlines, Harley-Davidson and more
• 28 de julio ·

  CNBC
  Comcast fails to add broadband subscribers for first time ever as economy slows